Additional file 1 of Gut microbiome for predicting immune checkpoint blockade-associated adverse events

Additional file 1: Table S1. Sample information for downloaded raw data. Table S2. Clinical characteristics of reviewed studies. Table S3. Clinical characteristics of in-house cohorts. Table S4. Differential microbial species between irAEs and non-irAEs in the integrated anti-CTLA-4 datasets. Table S5. Differential microbial species between irAEs and non-irAEs in the integrated anti-PD-1/PD-L1 datasets. Table S6. Wilcox-rank sum test for species filtering between with blocking on the ‘Study’. Important species (all P value < 0.1) compared between irAEs and non-irAEs and between responders and non-responders, were showcased in the data sheet, respectively. Table S7. Fourteen Species and relative abundance for model classifier. Table S8. Wilcox-rank sum test for pathway from PICRUST2 output. Differential pathways (FDR < 0.005) were showcased in the data sheet. Table S9. Wilcox-rank sum test for EC number from PICRUST2 output. Differential EC (FDR < 0.005) were showcased in the data sheet. Table S10. Differential genes (FDR < 0.5) from the colon tissue RNA sequencing (N = 9) were showcased in the data sheet. Table S11. Differential KEGG pathways (FDR < 0.05) analyzed by gene set enrichment analysis (GSEA).